151 related articles for article (PubMed ID: 37204419)
21. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.
Vijayaraghavan A; Efrusy MB; Goodman KA; Santas CC; Huh WK
Gynecol Oncol; 2010 Nov; 119(2):237-42. PubMed ID: 20713299
[TBL] [Abstract][Full Text] [Related]
23. Towards the elimination of cervical cancer in low-income and lower-middle-income countries: modelled evaluation of the effectiveness and cost-effectiveness of point-of-care HPV self-collected screening and treatment in Papua New Guinea.
Nguyen DTN; Simms KT; Keane A; Mola G; Bolnga JW; Kuk J; Toliman PJ; Badman SG; Saville M; Kaldor J; Vallely A; Canfell K
BMJ Glob Health; 2022 Mar; 7(3):. PubMed ID: 35241461
[TBL] [Abstract][Full Text] [Related]
24. Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system.
Winer RL; Tiro JA; Miglioretti DL; Thayer C; Beatty T; Lin J; Gao H; Kimbel K; Buist DSM
Contemp Clin Trials; 2018 Jan; 64():77-87. PubMed ID: 29113956
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study.
Kiendrébéogo JA; Sidibe ARO; Compaoré GB; Nacanabo R; Sory O; Ouédraogo I; Nawaz S; Schuind AE; Clark A
BMC Health Serv Res; 2023 Dec; 23(1):1338. PubMed ID: 38041075
[TBL] [Abstract][Full Text] [Related]
26. Cost-utility and budget impact analyses of cervical cancer screening using self-collected samples for HPV DNA testing in Thailand.
Kositamongkol C; Kanchanasurakit S; Mepramoon E; Talungchit P; Chaopotong P; Kengkla K; Chaisathaphol T; Saokaew S; Phisalprapa P
BMC Public Health; 2023 Dec; 23(1):2413. PubMed ID: 38049773
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.
Kim JJ; Ortendahl J; Goldie SJ
Ann Intern Med; 2009 Oct; 151(8):538-45. PubMed ID: 19841455
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.
Chow IH; Tang CH; You SL; Liao CH; Chu TY; Chen CJ; Chen CA; Pwu RF
Br J Cancer; 2010 Dec; 103(12):1773-82. PubMed ID: 21102588
[TBL] [Abstract][Full Text] [Related]
29. Mailed self-sample HPV testing kits to improve cervical cancer screening in a safety net health system: protocol for a hybrid effectiveness-implementation randomized controlled trial.
Montealegre JR; Anderson ML; Hilsenbeck SG; Chiao EY; Cantor SB; Parker SL; Daheri M; Bulsara S; Escobar B; Deshmukh AA; Jibaja-Weiss ML; Zare M; Scheurer ME
Trials; 2020 Oct; 21(1):872. PubMed ID: 33087164
[TBL] [Abstract][Full Text] [Related]
30. Design of a pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake in a U.S. healthcare system: The STEP trial.
Winer RL; Lin J; Anderson ML; Tiro JA; Meenan RT; Hansen K; Gao H; Sparks A; Greene DN; Kilgore-Martin S; Green BB; Buist DSM
Contemp Clin Trials; 2022 Nov; 122():106960. PubMed ID: 36241145
[TBL] [Abstract][Full Text] [Related]
31. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of High-Risk Human Papillomavirus by RNA Assay in Home Self-Collected Samples Among Underscreened People in North Carolina.
Lee F; Bukowski A; Spees LP; Wheeler SB; Brewer NT; Sanusi B; Hudgens MG; Jackson S; Barclay L; Carter A; Tang JH; Smith JS
Sex Transm Dis; 2022 Mar; 49(3):244-249. PubMed ID: 34535615
[TBL] [Abstract][Full Text] [Related]
33. Acceptability and ease of use of mailed HPV self-collection among infrequently screened women in North Carolina.
Anderson C; Breithaupt L; Des Marais A; Rastas C; Richman A; Barclay L; Brewer NT; Smith JS
Sex Transm Infect; 2018 Mar; 94(2):131-137. PubMed ID: 28866635
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of the screen-and-treat strategies using HPV test linked to thermal ablation for cervical cancer prevention in China: a modeling study.
Zhao XL; Zhao S; Xia CF; Hu SY; Duan XZ; Liu ZH; Wang YY; You TT; Gao M; Qiao YL; Basu P; Zhao FH
BMC Med; 2023 Apr; 21(1):149. PubMed ID: 37069602
[TBL] [Abstract][Full Text] [Related]
35. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.
Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G
Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056
[TBL] [Abstract][Full Text] [Related]
36. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness of strategies for cervical cancer prevention in India.
Chauhan AS; Prinja S; Srinivasan R; Rai B; Malliga JS; Jyani G; Gupta N; Ghoshal S
PLoS One; 2020; 15(9):e0238291. PubMed ID: 32870941
[TBL] [Abstract][Full Text] [Related]
38. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
[TBL] [Abstract][Full Text] [Related]
39. Patient perspectives on cervical cancer screening interventions among underscreened women.
Des Marais AC; Brewer NT; Knight S; Smith JS
PLoS One; 2022; 17(12):e0277791. PubMed ID: 36454891
[TBL] [Abstract][Full Text] [Related]
40. Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples.
Balasubramanian A; Kulasingam SL; Baer A; Hughes JP; Myers ER; Mao C; Kiviat NB; Koutsky LA
J Low Genit Tract Dis; 2010 Jul; 14(3):185-95. PubMed ID: 20592553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
